Quick Answer
Aquestive Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $44.55 million for the year ending 2025.
- Aquestive Therapeutics, Inc. showed a decrease of -22.6% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Aquestive Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Aquestive Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 33.9%.
- Historical annual values: Fiscal year 2025: $44.55 million | Fiscal year 2024: $57.56 million | Fiscal year 2023: $50.58 million | Fiscal year 2022: $47.68 million | Fiscal year 2021: $50.83 million | Fiscal year 2020: $45.85 million | Fiscal year 2019: $52.61 million | Fiscal year 2018: $67.43 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: